Pharma: Other News To Note
Thursday, August 2, 2012
Watson Pharmaceuticals Inc., of Parsippany, N.J., said it received approval from the FDA for its abbreviated new drug application for Budesonide Inhalation Suspension 0.25 mg/2mL and 0.5 mg/2mL, the generic equivalent for London-based AstraZeneca plc's Pulmicort Respules.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.